Literature DB >> 16188352

Serum concentration of AMDL DR-70 for the diagnosis and prognosis of carcinoma of the tongue.

Xiaodan Li1, Zhi Qiao, Xing Long, Jinxiong Wei, Yong Cheng.   

Abstract

The aim of this study was to discover the clinical value of the tumour marker AMDL DR-70 in a group of patients with cancer of the tongue. Serum concentrations of AMDL DR-70 were estimated by enzyme linked immuno-sorbent assay in 52 patients with carcinoma of the tongue and compared with 40 controls and 42 patients with benign lesions in the tongue. Thirty-nine patients with carcinoma of the tongue had results above 6 mg/L (75%), compared with 3/40 (7%) in healthy controls and 4/42 (10%) in those with benign tumours. The concentration of AMDL DR-70 in serum correlated significantly with 3-year survival.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16188352     DOI: 10.1016/j.bjoms.2004.11.020

Source DB:  PubMed          Journal:  Br J Oral Maxillofac Surg        ISSN: 0266-4356            Impact factor:   1.651


  4 in total

1.  Advantages of the AMDL-ELISA DR-70 (FDP) assay over carcinoembryonic antigen (CEA) for monitoring colorectal cancer patients.

Authors:  Andrea L Small-Howard; Holden Harris
Journal:  J Immunoassay Immunochem       Date:  2010

2.  Comparison of the serum fibrin-fibrinogen degradation products with cytokeratin 19 fragment as biomarkers in patients with lung cancer.

Authors:  Hee Jin So; Seok-Il Hong; Jin Kyung Lee; Yoon Hwan Chang; Sun Jung Kang; Young Jun Hong
Journal:  Biomed Rep       Date:  2014-07-11

3.  Role of DR-70 immunoassay in suspected malignant pleural effusion.

Authors:  Amitabha Sengupta; Kaushik Saha; Debraj Jash; Sourindra Nath Banerjee; Nirendra Mohan Biswas; Atin Dey
Journal:  Lung India       Date:  2013-10

4.  Prognostic Significance of DR-70 Levels in Dysplastic Colorectal Polyps.

Authors:  Atakan Yesil; Gul Babacan Abanonu; Yasar Colak; Nurcan Paker; Can Gonen
Journal:  Gastroenterol Res Pract       Date:  2013-11-21       Impact factor: 2.260

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.